20S Immunoproteasome (human) (untagged)

CHF 507.00
In stock
SBB-PP0004-C02525 µgCHF 507.00
More Information
Product Details
Product Type Protein
Source/Host Human PBMCs

Human 20S Immunoproteasome.

Crossreactivity Human

Experiments should be carried out at 20S immunoproteasome concentrations between 2-5nM. The 20S immunoproteasome is commonly associated with the 19S, PA28 α/β, or the PA28γ regulatory complexes. If choosing to omit PA28 during use, 20S must be chemically activated by addition of 0.035%SDS in final assay buffers.

MW ~700kDa
Purity ≥95% (SDS-PAGE)
Concentration Lot dependent.
Formulation Liquid. In 50mM HEPES pH 7.5, 100mM sodium chloride, 1mM TCEP.
Other Product Data

Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by South Bay Bio.
Shipping and Handling
Shipping DRY ICE
Short Term Storage -80°C
Long Term Storage -80°C
Handling Advice Aliquot to avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -80°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

The 20S immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of α-subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasomes these subunits (ß1, ß2, ß5) are replaced by three inducible subunits: PSMB9, PSMB10 and PSMB8, (ß1i, ß2i, ß5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T cells. 20S immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.